Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better?
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical (without peer review) |
| MU Faculty or unit | |
| Citation | |
| Description | For many decades, radiotherapy (RT) has been the primary treatment for patients with limited as well as extended brain metastases. Whole brain radiotherapy (WBRT) was practically the only method often used even in the case of a single brain metastasis (BM), depending on the availability of special RT systems such as the gamma knife. Also nowadays, the availability of modern RT methods is often a decisive factor. In recent years, however, we have witnessed almost revolutionary changes with many new studies in patients with BM defining quality of life and neurocognitive function as important outcomes.1 For many decades we have rather witnessed a lack of interest in multiple BM patients who dogmatically had a very poor prognosis and no treatment method had even the theoretical potential to be superior to WBRT. Thus, it is not surprising that there was not much interest in these studies. The greater the ignorance, the greater the dogmatism (Sir William Osler, 1849–1919). |
| Related projects: |